Background
==========

Acute myeloid leukemia (AML) is a common hematological malignancy with myeloblast proliferation in the bone marrow of adults and children. AML patients have highly heterogeneous disease course and outcomes. According to the French-American-British (FAB) classification, AML is defined as having eight subtypes: M0, M1, M2, M3, M4, M5, M6, and M7 \[[@b1-medscimonit-23-4705],[@b2-medscimonit-23-4705]\].

It has been estimated that 50%--60% of AML patients display cytogenetic abnormalities and significantly heterogeneous outcomes \[[@b3-medscimonit-23-4705],[@b4-medscimonit-23-4705]\]. Cytogenetic abnormalities include chromosomes translocation, inversion, and deletion; some chromosome abnormalities, such as t(8;21), t(16;16), inv(16), and t(15;17), predict better prognosis of AML patients. Chromosomes abnormalities, including −5,−7, abn(3q), del(5q) and other complex karyotypes, predict poor prognosis \[[@b5-medscimonit-23-4705]\]. AML patients with normal karyotypes, *FLT3* mutation, and negative mutation of *NPM1* possess intermediate prognosis. A number of groups have endeavored to come to an agreement on prognosis risk evaluation of AML chromosomes abnormalities \[[@b6-medscimonit-23-4705]--[@b9-medscimonit-23-4705]\], but discrepancy exists among different group standards. For example, del(7q) is considered to be an intermediate-risk abnormality based on CALGB standards but it is considered to be a poor-risk based on SWOG standards \[[@b10-medscimonit-23-4705]\].

Although there has been progress in understanding the mechanisms of pathogenesis of AML, it is still difficult to predict clinical outcomes for AML patients. Over the past decades, the prognostic prediction of AML patients has largely depended on cytogenetic abnormalities. More recently, molecular genetic changes have been identified to predict prognosis and guide clinical treatment. Molecular genetic changes consist of mutations of *CEBPA, NPM1, FLT3,* and *c-KIT. CEBPA* mutation and *NPM1* mutation (absence of *FLT3* mutation) suggest a favorable prognosis for AML patients with longer complete remission duration and overall survival. However, *c-KIT* mutation suggests an intermediate prognosis, and *FLT3* mutation suggests an unfavorable prognosis \[[@b11-medscimonit-23-4705]\].

In this study, we applied bioinformatics and univariate Cox regression analysis to identify the miRNAs and target-genes associated with overall survival of AML patients, and aimed to provide valuable information for further AML patient classification and therapy planning.

Material and Methods
====================

Patients and samples
--------------------

Two hundred study patients with AML were retrieved from The Cancer Genome Atlas (TCGA) data portal. The full clinical dataset was downloaded (up to March 16, 2015). The exclusion criteria for AML patients were as follows: 1) history of other malignancy; 2) history of AML treatment; and 3) samples with clinical data but without miRNA or mRNA sequence data. In the TCGA database, 49 AML patients had a history of treatment before collection of blood samples and all of them received treatment with hydroxyurea. Overall, 120 AML patients with available corresponding clinical data, including age, gender, race, vital status, and follow-up, were included in our study.

miRNA and mRNA expression data
------------------------------

The miRNA and mRNA expression data (level 3) of the AML patients were downloaded from the TCGA data portal (up to March 16, 2015). The miRNA and mRNA expression profiling was generated from the Illumina Genome Analyzer sequencing platforms (Illumina Inc., San Diego, CA, USA).

Survival analysis
-----------------

The association between miRNA expression and overall survival was carried out using univariate Cox regression. A set of miRNAs that significantly correlated with survival was identified with the threshold of *p*-value less than 0.05. The association between mRNA expression and overall survival was sequentially performed using univariate Cox regression; the threshold was a *p*-value less than 0.05, which indicated that a set of mRNAs was significantly associated with survival. Hazard ratio (HR) \>1 indicated a risk factor associated with AML survival and HR \<1 indicated a protective factor associated with AML survival.

Identification of target-genes of miRNAs
----------------------------------------

To obtain the target-genes of miRNAs associated with AML survival, the miRNAs were integrated into the mirWalk database (*<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>*), in which the correlations between target-genes and miRNAs have been confirmed. Six algorithms including RNA22, miRanda, miRDB, miRWalk, PICTAR2, and Targetscan were conducted to predict target-genes of miRNAs. The genes, simultaneously predicted by more than four algorithms, were identified as the target-genes of the miRNAs.

miRNA-target gene network
-------------------------

miRNAs associated with AML survival and target-genes associated with AML survival were identified to construct the interaction network using Cytoscape software (*<http://cytoscape.org>*). In the miRNA-target gene network, a circular node represented mRNA and a rectangle node represented miRNA, and their association was represented by a solid line.

KEGG pathway enrichment
-----------------------

The underlying functions of target-genes associated with AML survival were predicted by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis using the GeneCodis software. FDR \<0.05 was the cut-off for selecting significant KEGG pathway.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

Total RNA of peripheral blood of AML patients was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The SuperScript III Reverse Transcription Kit (Invitrogen, Carlsbad, CA, USA) was used to synthesize the cDNA according to the manufacturer's instructions. Then qRT-PCR reactions were performed using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on the Applied Biosystems 7500 (Applied Biosystems, Foster City, CA, USA). For detection of miRNA expression level, we used miRcute miRNA First-Strand cDNA Kit (Tiangen, Bejing, China) and miRcute miRNA qPCR Detection Kit (Tiangen, Bejing, China). U6 and β-actin were used as internal controls for miRNA and mRNA expression, respectively. The relative expression of target-genes was calculated using the ΔCT equation. The PCR primers were used as follows:

1.  IL15RA forward-5′CAACAGCCAAGAACTGGGAAC3′;

2.  IL15RA reverse-5′AGTTTGCCTTGACTTGAGGTAGC3′;

3.  CD44 forward-5′ ATCATCTTGGCATCCCTCTTG 3′;

4.  CD44 reverse-5′TGTCCTCCACAGCTCCATTG 3′;

5.  β-actin forward-5′ CTGAAGTACCCCATCGAGCAC 3′;

6.  β-actin reverse- 5′ ATAGCACAGCCTGGATAGCAAC 3′;

7.  hsa-miR-200c forward-5′ CGTCTTACCCAGCAGTGTTTG3′;

8.  hsa-miR-425 forward-5′ AATGACACGATCACTCCCGTTGA 3′;

9.  U6 forward-5′ CTCGCTTCGGCAGCACA 3′;

10. U6 reverse-5′ AACGCTTCACGAATTTGCGT 3′.

Statistical analysis
--------------------

At least three independent experiments were performed for statistical evaluation. The SPSS19.0 program was used for general statistical analysis. The qRT-PCR experimental data were expressed as means ± standard deviation. The statistical significance was evaluated using the Student's *t*-test; *p*\<0.05 was considered a significant difference.

The peripheral blood samples for qRT-PCR examination were obtained from AML patients diagnosed at the Department of Hematology, Taian City Central Hospital. Our study was approved by the Ethics Committee of Taian City Central Hospital and complied with the Declaration of Helsinki. All participants provided written informed consent to participate in this study.

Results
=======

miRNAs associated with survival time of AML patients
----------------------------------------------------

The miRNA expression and survival time of AML patients were obtained from the TCGA database and univariate Cox regression analysis was performed. We obtained 14 miRNAs associated with survival time; the threshold was *p*\<0.05, as shown in [Table 1](#t1-medscimonit-23-4705){ref-type="table"}. HR \>1 indicated a risk factor and HR \<1 indicated a protective factor. In our study, hsa-mir-1201, hsa-mir-1978, and hsa-mir-425 were identified as risk factors, and hsa-mir-10b, hsa-mir-193b, hsa-mir-194-1, hsa-mir-196a-1, hsa-mir-1976, hsa-mir-200c, hsa-mir-23b, hsa-mir-30a, hsa-mir-452, hsa-mir-509-1, and hsa-mir-589 were identified as protective factors for survival time of AML patients.

mRNA associated with survival time of AML patients
--------------------------------------------------

The mRNA expression and survival time of AML patients were obtained from the TCGA database and univariate Cox regression analysis was performed. We obtained 830 mRNAs associated with survival time; the threshold was *p*\<0.05, as shown in [Table 2](#t2-medscimonit-23-4705){ref-type="table"}. We identified 830 mRNAs associated with AML survival including 482 mRNAs identified as risk factors and 348 mRNAs identified as protective factors (data not shown). The top 20 risk factor mRNAs and top 20 protective factor mRNAs associated with survival time (*p*\<0.05) are presented in [Table 2](#t2-medscimonit-23-4705){ref-type="table"}; POLR3C, TULP2, CIRBP, WNT7A, and FARS2 were the top 5 risk factor mRNAs. SPIC, ZBTB2, VCAM1, AMPD1, and SOX9 were the top 5 protective factor mRNAs associated with survival time of AML patients.

The target-gene prediction of miRNA associated with survival time
-----------------------------------------------------------------

The target genes of 14 miRNAs associated with survival time were predicted and target-genes of 12 miRNAs were available in the mirWalk database. A total of 607 miRNA-target gene pairs were obtained, as shown in the [Supplementary Table 1](#s1-medscimonit-23-4705){ref-type="supplementary-material"}. The predictive target-genes of miRNAs ([Figure 1](#f1-medscimonit-23-4705){ref-type="fig"}) and mRNAs associated with survival time overlapped; 109 predictive target-genes associated with survival time were obtained (underlined genes in [Supplementary Table 1](#s1-medscimonit-23-4705){ref-type="supplementary-material"}). GTSF1, RTN4R, and CD44 were the top risk factor target-genes associated with AML survival.

Regulatory network construction of miRNA and mRNA associated with survival time
-------------------------------------------------------------------------------

To obtain insights into the regulatory relationship between the 12 miRNAs and 109 target-genes associated with survival time, a regulatory network was constructed. As shown in [Figure 1](#f1-medscimonit-23-4705){ref-type="fig"}, rectangle nodes represent miRNAs associated with survival time and circular nodes represent mRNAs associated with survival time. The miRNAs hsa-mir-30a, hsa-mir-589, hsa-mir-10b, hsa-mir-452, and hsa-mir-200c had high connectivity with the mRNAs associated with AML patient survival time, and regulated 27, 24, 22, 22, 21 mRNAs, respectively.

KEGG pathway enrichment
-----------------------

KEGG pathway analysis was used to identify biological functions of miRNA target-genes. In all, 105 of the 109 target-genes associated with survival time were enriched in the KEGG database. Four signaling pathways were significantly enriched, including pancreatic secretion, calcium signaling pathway, natural killer cell mediated cytotoxicity, and Alzheimer's disease, as shown in [Table 3](#t3-medscimonit-23-4705){ref-type="table"}.

qRT-PCR validation of miRNA and mRNA associated with survival
-------------------------------------------------------------

To validate the expression status of miRNAs and mRNAs associated with survival, miRNAs (hsa-miR-200c and hsa-miR-425) and mRNA (IL15RA and CD44) were preliminarily quantified by qRT-PCR. Sixteen AML patients were divided into two groups, a low-moderate risk group and a high-risk group, based on karyotype and gene mutation detection according to the standards of the Medical Research Council. As [Figure 2A, 2C, and 2D](#f2-medscimonit-23-4705){ref-type="fig"} show, the expression levels of IL15RA (*p*=0.0003), CD44 (*p*=0.028) and hsa-miR-425 (*p*=0.053) were significant upregulated in the high-risk group compared with the low-moderate risk group. As [Figure 2B](#f2-medscimonit-23-4705){ref-type="fig"} shows, the expression level hsa-miR-200c (*p*=0.033) was significant downregulated in the high-risk group compared with the low-moderate risk group.

Discussion
==========

In our study, hsa-mir-425 was the top risk factor associated with AML survival, as shown in [Table 1](#t1-medscimonit-23-4705){ref-type="table"}. It has been reported that mir-425-5p is upregulated in human gastric cancer and contributes to gastric cancer cell proliferation, invasion and metastasis *in vitro* and *in vivo* \[[@b12-medscimonit-23-4705]--[@b14-medscimonit-23-4705]\]. Over-expression of miR-425 enhances cell proliferation, colony formation, and cell metastasis in esophageal squamous cell carcinoma by targeting SMAD2 \[[@b15-medscimonit-23-4705]\]. Ge et al. reported that mir-425 was significantly associated with recurrence-free survival (RFS) and overall survival of chromophobe renal cell carcinoma, and miRNA expression signatures including mir-191, mir-19a, mir-210, and mir-425, were identified as predictors of clinical prognosis \[[@b16-medscimonit-23-4705]\].

In our study, hsa-mir-30a was the top protective factor associated with AML survival ([Table 1](#t1-medscimonit-23-4705){ref-type="table"}). Over-expression of BCR-ABL1 is associated with chronic myeloid leukemia; and downregulation of mir-30a enhances BCR-ABL expression and promotes chronic myeloid leukemia tumorigenesis \[[@b17-medscimonit-23-4705]\]. The *MYBL2* gene encodes a transcription factor; and over-expression of *MYBL2* could be implicated in tumorigenesis of colorectal cancer and AML \[[@b18-medscimonit-23-4705],[@b19-medscimonit-23-4705]\]. In AML, MYBL2 over-expression is associated with the miRNA-30 family (including mir-30a, mir-30b, mir-30c) and predicts unfavorable prognosis of AML patients \[[@b19-medscimonit-23-4705],[@b20-medscimonit-23-4705]\].

CD44 was one of the top three risk factor target-genes associated with AML survival. A number of studies have reported that CD44 is associated with AML survival. In elderly patients with refractory AML, the overall survival of patients with PTEN-positive and CD44-negative expression is longer than patients with PTEN-negative and CD44-positive expression \[[@b21-medscimonit-23-4705]\]. Knockdown of CD44 enhances chemo-sensitivity of AML cells to adriamycin (ADM) and cytosine arabinoside (Ara-C) \[[@b22-medscimonit-23-4705]\]. CD44 activation enhances primary acute monoblastic leukemia blast survival and increases apoptosis resistance of THP-1 monoblastic leukemia cells. Moreover, CD44 activation upregulates the expression of anti-apoptotic Mcl-1 protein, which is essential for apoptosis resistance of THP-1 cells \[[@b23-medscimonit-23-4705]\]. Calcium signaling pathway was one of the significantly enriched pathways in our study ([Table 3](#t3-medscimonit-23-4705){ref-type="table"}). Calcium can act in signal transduction resulting from activation of ion channels or as a second messenger. Calcium signaling through ion channels is important to maintain depolarization of the heart and neuronal synaptic transmission. Calcium ions play a vital role in muscle contraction, neuronal transmission, cell motility, cell growth or proliferation \[[@b24-medscimonit-23-4705]--[@b27-medscimonit-23-4705]\]. It has been reported that calcium signaling pathway is related to progression and development of various cancers including lung adenocarcinoma \[[@b28-medscimonit-23-4705]\], colorectal cancer \[[@b29-medscimonit-23-4705]\], glioblastoma \[[@b30-medscimonit-23-4705]\], breast cancer \[[@b31-medscimonit-23-4705]\], and Burkitt lymphoma \[[@b32-medscimonit-23-4705]\]. Calcium signaling pathway may play a key role in the progression and development of AML.

Natural killer cell mediated cytotoxicity was one of the significant enrichment KEGG pathways in our study ([Table 3](#t3-medscimonit-23-4705){ref-type="table"}). Natural killer cell mediated cytotoxicity contributes to the innate immune response against numerous malignancies. Progression and development of malignancy is promoted by tumor cells escaping from immune surveillance of immune effector cells, including natural killer cells \[[@b33-medscimonit-23-4705]\]. The phenomenon of tumor cells escaping from immune surveillance is observed in numerous malignancies including breast cancer \[[@b34-medscimonit-23-4705]\], head-and-neck squamous carcinoma \[[@b35-medscimonit-23-4705]\], and leukemia. Leukemia stem cells play a central role in the relapse and refractory of AML. Leukemic stem-like cells from AML cell line KG1a cells are resistant to chemotherapy and natural killer cell-mediated cytotoxicity \[[@b36-medscimonit-23-4705]\]. Acute lymphoblastic leukemia could resist natural killer cell-mediated cytotoxicity \[[@b37-medscimonit-23-4705]\].

Calcium signaling pathway and natural killer cell mediated cytotoxicity correlate with the progression and development of numerous tumors. It has been suggested that these two pathways may play key roles in AML progression and contribute to AML survival.

We identified the miRNAs and target-genes associated with AML survival. In our study, IL15RA, TNIP1, CD44, and hsa-mir-425 were risk-factor miRNA/target-genes associated with AML survival. In addition, hsa-mir-10b and hsa-mir-30a were protective-factor miRNAs associated with AML survival. As [Figure 2](#f2-medscimonit-23-4705){ref-type="fig"} shows, IL15RA, CD44, and hsa-miR-425 were obviously upregulated in the high-risk group, and hsa-miR-200c was significantly downregulated in the high-risk group compared with the low-moderate risk group of AML patients. The qRT-PCR results were in accordance with other study results.

There were limitations to our study. First, although the miRNAs and mRNAs associated with survival time of AML patients identified in our study may have implications in the understanding of AML tumorigenesis and development of targeted therapy of AML, the roles of identified miRNAs and mRNAs in AML need to be further explored in laboratory work. Second, although we obtained miRNAs and target-genes associated with AML survival, we did not construct a prognostic model of AML survival. In future work, we will use miRNAs and target-genes to construct a prognostic signature to predict survival time of AML patients, and then verify the prognostic signature through clinical observations.

Conclusions
===========

A number of miRNAs and mRNAs that correlated with survival of AML patients were identified in our study, which might provide valuable information for identification of potentially prognostic biomarker for AML survival.

Supplementary Table
===================

###### 

The target-genes of miRNAs associated with AML survival.

  miRNA            Count of targets   Count of target related to survival   Target mRNAs
  ---------------- ------------------ ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa-mir-10b      66                 22                                    JPH1, TRIM25, AXL, HTATSF1, VGLL3, SLCO2B1, [RTN4R]{.ul}, C17orf28, [CD44, IGF2BP2]{.ul}, ITGB3, [NRL, SCARF1,]{.ul} HSPA12A, RDH10, SASH1, ANKRD13A, KIAA1024, MAP1LC3B, SFRP1, [COPS7B, BTN2A1,]{.ul} NUDT4, FLRT2, SPTY2D1, ERRFI1, LTBP2, LRRC59, PPP1R15B, DNAJC5, [C16orf48, GGT7,]{.ul} BAG5, [WDR78, GPR44]{.ul}, FBLIM1, [SEZ6]{.ul}, TMTC1, [RPS23,]{.ul} CALU, [DNAL4]{.ul}, GLRX3, [DOHH]{.ul}, ZSCAN22[, ST7L]{.ul}, ELOVL2, [BAHD1, MPI, AMN, GALE,]{.ul} SIX4, KIAA1751, KIAA1045, INSIG2, TMEM2, ZFYVE27, MTMR3, ARNT2, FHL3[, DAND5]{.ul}, FABP2[, LYVE1]{.ul}, PITPNA, LY6K, ADIPOQ, [ST6GALNAC6]{.ul}
  hsa-mir-1201     2                  0                                     KCTD14, PTGIS
  hsa-mir-193b     44                 15                                    SOX9, SDC1, TRIM25, C1QC, HECW1, EPB41L4B, ADAMTSL3, RHOU, ITGB3, [SCARF1]{.ul}, SVEP1, TMEM30A, PTPRE, ANKRD13A, SLC35F3, [CEND1]{.ul}, [MRPS18B]{.ul}, NUDT4, TMED10, ZNF423, DNAJC5, [C16orf48]{.ul}, [ATP2A3]{.ul}, EAF1, [LRRC8A]{.ul}, RNF138, CACNA1E, CALU, [NUDT12]{.ul}, [C11orf49]{.ul}, [ST7L]{.ul}, [BRAF]{.ul}, [PTTG1IP]{.ul}, SNX30, ARHGAP29, COMMD9, SIX4, [6-Sep]{.ul}, KIAA1045, [ZFYVE27]{.ul}, [DLST]{.ul}, YAP1, [DCTN5]{.ul}, TAPT1
  hsa-mir-194-1    1                  0                                     IL22
  hsa-mir-196a-1   3                  2                                     [IKBKB]{.ul}, COL3A1, [HMGA1]{.ul}
  hsa-mir-200c     95                 21                                    IGF1, ADAMTS9, PTPN12, C10orf81, VGLL3, COL1A2, OXR1, MRO, C1orf124, CEBPG, EPB41L4B, GZF1, [CD44]{.ul}, NTRK2, [SLC9A3R2]{.ul}, [KLF17]{.ul}, ITGB3, [TTC5]{.ul}, HSPA12A, CDH11, RDH10, C16orf72, SASH1, TMEM47, KIAA1486, KIAA1024, MAP1LC3B, SFRP1, [YES1]{.ul}, [BTN2A1]{.ul}, PHACTR3, RND3, RND3, NUDT4, TOR1AIP1, TJP1, SPTY2D1, GNG12, ERRFI1, NLGN4X, TMED10, ZNF423, DNAJC5, [ATP2B1]{.ul}, BAG5, [ATF7]{.ul}, SNAI2, SNAI2, LRRC8A, [IKBKB]{.ul}, TMTC1, RNF138, [RPS23]{.ul}, CALU, [ATXN7L1]{.ul}, FUBP3, ALCAM, [AHRR]{.ul}, ZFPM2, ZFPM2, ING2, TSPAN12, CLSPN, MPDZ, SCD, [TET1]{.ul}, FBXL3, [MAMDC2]{.ul}, GPR116, ELOVL2, MTDH, [TMEM25]{.ul}, SNX30, ARL5A, MSR1, SPRED1, PRKAR2B, [TERF2]{.ul}, MMD, [6-Sep]{.ul}, [IAH1]{.ul}, MTMR1, [SPON1]{.ul}, PAK1, HSDL1, LCP1, IL33, YAP1, [SEMA5A]{.ul}, PRKAR1A, PITPNA, LY6K, ADIPOQ, [HS3ST3A1]{.ul}, COPS8
  hsa-mir-23b      86                 16                                    ZBTB2, CXCL12, CXCL12, EBF3, IGF1, RASSF2, AXL, VGLL3, [ITFG2]{.ul}, HECW1, GNA14, OXR1, PCDH17, MAGI1, EPB41L4B, GZF1, C17orf28, PROS1, ITIH5, EPSTI1, ITGB3, HSPA12A, [NDUFA7]{.ul}, RDH10, [RSPH3]{.ul}, C16orf72, [LHX4]{.ul}, KIAA1024, SFRP1, NUDT4, FLRT2, KAL1, [ZSCAN18]{.ul}, TJP1, SPTY2D1, NLGN4X, LIFR, TMED10, ZNF423, SIGLEC1, EAF1, RGS13, DCLK1, CHUK, GPRIN1, CACNA1E, CALU, PCDH18, ALCAM, GLRX3, CPEB2, TSPAN12, TXNDC16, [SCN4A]{.ul}, CD163, DDX60L, INSR, [ZSCAN22]{.ul}, [C11orf59]{.ul}, [ST7L]{.ul}, PDK4, PDK4, ELOVL2, LTV1, [WBP2]{.ul}, USP31, YTHDF1, SNX30, [BRD8]{.ul}, YY1, SLC8A1, [TERF2]{.ul}, SIX4, ELOVL3, TMED5, INSIG2, TMEM2, [ZNF85]{.ul}, ARNT2, [SEMA5A]{.ul}, FCRL5, [APOBEC3F]{.ul}, PITPNA, GLP1R, [C14orf119]{.ul}, TAPT1
  hsa-mir-30a      102                27                                    SOX9, CXCL12, EBF3, MOCS1, SPOCK3, UBN1, VGLL3, NXN, [RTN4R]{.ul}, FRZB, HECW1, OXR1, TUSC3, PCDH17, EPB41L4B, [TTC9C]{.ul}, GZF1, [TNIP1]{.ul}, MTHFD2, CACNA2D1, [RARG]{.ul}, LRRC8D, [SLC9A3R2]{.ul}, ITGB3, ITGB3, [RAB34]{.ul}, [TCTE3]{.ul}, RDH10, TMEM30A, NTRK3, TMEM47, ANKRD13A, [VAT1]{.ul}, SLC35F3, KIAA1024, MAP1LC3B, [YES1]{.ul}, [COPS7B]{.ul}, DBF4, RND3, KLHL4, SPTY2D1, ERRFI1, LTBP2, LIMCH1, LIFR, TMED10, TMED10, PPP1R15B, FCN1, [ATP2B1]{.ul}, [WDR78]{.ul}, EAF1, PRG4, CBX3, [LRRC8A]{.ul}, UBE2J1, UBE2J1, TMTC1, RNF138, CALU, [MRPS24]{.ul}, [MLLT1]{.ul}, MAP6, FUBP3, CPEB2, [C19orf50]{.ul}, DPYSL2, [VPS39]{.ul}, [ZSCAN22]{.ul}, [TET1]{.ul}, FBXL3, ELOVL2, MTDH, [RGMB]{.ul}, PTGIS, [BAHD1]{.ul}, [MPI]{.ul}, SNX30, ARHGAP29, [C9orf123]{.ul}, COMMD9, MMD, [CAPN11]{.ul}, SIX4, PPID, [6-Sep, K]{.ul}IAA1751, INSIG2, TMEM2, TMEM87A, TMEM87A, MTMR1, SH3KBP1, [SPON1]{.ul}, TPRG1L, HSDL1, LCP1, LCP1, PRKAR1A, [HMGA1]{.ul}, LY6K
  hsa-mir-425      57                 20                                    SOX9, JPH1, IGF1, TRIM25, [HIST2H2BE]{.ul}, VGLL3, DCN, C17orf28, ITIH5, CCDC126, ITGB3, [TMEM42]{.ul}, TMEM30A, C16orf72, GABRA2, ANKRD13A, [ZNF625]{.ul}, KIAA1486, SFRP1, PHACTR3, [SNED1]{.ul}, RND3, NUDT4, FLRT2, SPTY2D1, GNG12, NLGN4X, LRRC59, TMED10, ZNF423, [ZNF70]{.ul}, [ATP2A1]{.ul}, EAF1, RGS13, LRRC8A, [IKBKB]{.ul}, [SEZ6]{.ul}, [BMP8A]{.ul}, CALU, [AHRR]{.ul}, CPEB2, [SCN4A]{.ul}, DPYSL2, [DOHH]{.ul}, [PIGZ]{.ul}, [BANP]{.ul}, [ZSCAN22]{.ul}, [MUS81]{.ul}, GPR116, USP31, [C9orf123]{.ul}, TSPYL1, [KLRD1]{.ul}, MTMR3, HSDL1, [DLST]{.ul}, [MCOLN3]{.ul}
  hsa-mir-452      81                 22                                    EBF3, IGF1, TRIM25, RASSF2, PTPN12, VGLL3, PGBD5, FMO2, MRO, PCDH17, C1orf124, MAGI1, [IGF2BP2]{.ul}, [ALS2CL]{.ul}, RAD21, HSPA12A, ANK2, APOL6, SASH1, TMEM47, PTPRE, KIAA1486, [SNUPN]{.ul}, MAP1LC3B, SFRP1, [YES1]{.ul}, [SNED1]{.ul}, FLRT2, GNG12, NLGN4X, LIFR, TMED10, [GRAP, ATP2B1]{.ul}, [ZNF70]{.ul}, [GPR44]{.ul}, FAM101B, SNAI2, DCLK1, CHUK, DENND2A, COL3A1, TMTC1, [BMP8A]{.ul}, RNF138, CACNA1E, PCDH18, [UFC1]{.ul}, [ATXN7L1]{.ul}, EFEMP1, [AHRR]{.ul}, CPEB2, DPYSL2, [MZF1]{.ul}, DDX60L, [GAPDHS]{.ul}, SCD, [TET1]{.ul}, SLC44A1, FBXL3, ELOVL2, ELTD1, [RGMB]{.ul}, YTHDF1, SNX30, SLC8A1, PRKAR2B, [C9orf123]{.ul}, COMMD9, TSPYL1, [KLRD1]{.ul}, KIAA1045, TMEM87A, [AGXT]{.ul}, ARNT2, [GMPR2]{.ul}, YAP1, [NUP214]{.ul}, [DCTN5]{.ul}, TAPT1, COPS8
  hsa-mir-509-1    1                  0                                     NTRK3
  hsa-mir-589      69                 24                                    ZBTB2, [GTSF1]{.ul}, C1QC, RASSF2, [HIST2H2BE]{.ul}, VGLL3, NXN, SLCO2B1, PGBD5, FMO2, MRO, PCDH17, DCN, EPB41L4B, CCDC126, ITGB3, [NRL]{.ul}, CDH11, SVEP1, ANK2, TMEM130, EFS, C16orf72, SASH1, PTPRE, [ULK4]{.ul}, [IL15RA]{.ul}, [VAT1]{.ul}, KIAA1486, SFRP1, [YES1]{.ul}, [ZNF609]{.ul}, GNG12, ERRFI1, LIFR, PPP1R15B, DNAJC5, BAG5, FAM101B, CBX3, TMTC1, [BMP8A]{.ul}, [RPS23]{.ul}, [ATXN7L1]{.ul}, [MLLT1]{.ul}, [LAT]{.ul}, DPYSL2, SCD, [ZSCAN22]{.ul}, TOR1B, FBXL3, [ST7L]{.ul}, [BAHD1]{.ul}, [FAM46B]{.ul}, COMMD9, SIX4, KIAA1751, [BARHL1]{.ul}, PAK1, [FHL3]{.ul}, FABP2, YAP1, [SEMA5A]{.ul}, PITPNA, [MEOX1]{.ul}, [DCTN5]{.ul}, [HS3ST3A1]{.ul}, [BCAT2]{.ul}, COPS8
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###### 

miRNAs associated with AML survival.

  miRNA            Beta       HR        95 %CI (low)   95%CI (high)   *P*-value
  ---------------- ---------- --------- -------------- -------------- -----------
  hsa-mir-425      0.78098    2.1836    1.1866         4.0184         0.012081
  hsa-mir-1978     0.77576    2.1722    1.1343         4.1601         0.019282
  hsa-mir-1201     0.65208    1.9195    1.0231         3.6012         0.042227
  hsa-mir-589      −0.64776   0.52322   0.27722        0.98751        0.045633
  hsa-mir-23b      −0.65778   0.518     0.28334        0.94702        0.03261
  hsa-mir-196a-1   −0.65789   0.51794   0.2715         0.98809        0.045895
  hsa-mir-200c     −0.66085   0.51641   0.27139        0.98263        0.044075
  hsa-mir-509-1    −0.6679    0.51278   0.27829        0.94487        0.032206
  hsa-mir-1976     −0.69919   0.49699   0.25874        0.95462        0.035777
  hsa-mir-194-1    −0.72271   0.48543   0.24412        0.9653         0.039331
  hsa-mir-193b     −0.80362   0.4477    0.22526        0.88981        0.021841
  hsa-mir-452      −0.82757   0.43711   0.2298         0.83143        0.011644
  hsa-mir-10b      −0.84543   0.42937   0.22207        0.8302         0.011965
  hsa-mir-30a      −0.85097   0.427     0.22278        0.81843        0.010358

HR -- hazard ration; CI -- confidence interval; Beta -- regression coefficient; AML -- acute myeloid leukemia.

###### 

mRNAs associated with AML survival.

  Gene symbol                     Beta       HR            95%CI (low)   95%CI (high)   *P*-value
  ------------------------------- ---------- ------------- ------------- -------------- -----------
  **Risky mRNAs (top 20)**                                                              
  POLR3C                          1.299177   3.666278842   1.822439      7.375612       0.00027
  TULP2                           1.271691   3.56687887    1.659339      7.667284       0.001126
  CIRBP                           1.212915   3.363273616   1.676527      6.747048       0.000638
  WNT7A                           1.13283    3.104429621   1.563505      6.164025       0.001207
  FARS2                           1.128418   3.090761914   1.589044      6.011672       0.000886
  HSBP1L1                         1.101514   3.008717605   1.49912       6.038464       0.001941
  SPATA24                         1.093419   2.984460963   1.507142      5.909864       0.001708
  GTSF1                           1.088786   2.97066512    1.516522      5.81914        0.001504
  LOC150197                       1.087166   2.965857274   1.512986      5.813873       0.001547
  PRR4                            1.085033   2.959538025   1.426825      6.138709       0.003558
  ZSCAN16                         1.059951   2.886230787   1.496316      5.567227       0.001565
  tAKR                            1.057348   2.878727159   1.41916       5.83942        0.003389
  TMCO6                           1.048799   2.854219977   1.445137      5.637231       0.002525
  GLRA1                           1.046813   2.848559639   1.431752      5.667387       0.002858
  KCNQ5                           1.040786   2.83144076    1.412616      5.675325       0.003349
  CCDC61                          1.030272   2.801828015   1.446379      5.427514       0.002258
  METRN                           1.014433   2.757800065   1.305514      5.825647       0.007844
  HIST2H2BF                       1.012048   2.751231083   1.452881      5.209838       0.001892
  RTN4R                           1.011228   2.748975915   1.384951      5.456416       0.003839
  PKP3                            1.008338   2.741042689   1.428346      5.26015        0.002429
  **Protective mRNAs (top 20)**                                                         
  SPIC                            −1.31893   0.2674205     0.129581      0.551884       0.00036
  ZBTB2                           −1.27059   0.2806665     0.142188      0.554012       0.00025
  VCAM1                           −1.26516   0.2821953     0.142927      0.557167       0.000267
  AMPD1                           −1.21566   0.2965143     0.147273      0.59699        0.000662
  SOX9                            −1.19687   0.3021391     0.15331       0.595449       0.000545
  CXCL10                          −1.18323   0.306289      0.146201      0.641673       0.001714
  MOCS1                           −1.17538   0.3087017     0.155751      0.611851       0.000759
  CXCL12                          −1.16587   0.3116504     0.159361      0.60947        0.000657
  SDC3                            −1.14539   0.3181006     0.16393       0.617262       0.000708
  SDC1                            −1.14055   0.3196427     0.161413      0.632981       0.001068
  FER1L4                          −1.12792   0.3237057     0.160942      0.651075       0.001558
  TRIM25                          −1.12791   0.32371       0.161198      0.650058       0.00152
  EBF3                            −1.1233    0.3252052     0.169878      0.622555       0.000698
  CDH15                           −1.11564   0.3277049     0.15995       0.671401       0.002299
  CD163L1                         −1.10857   0.3300322     0.16721       0.651404       0.001396
  IGF1                            −1.10036   0.3327518     0.171385      0.646052       0.001152
  ADAMTS9                         −1.07894   0.3399546     0.174127      0.663706       0.001573
  C10orf81                        −1.0656    0.34452       0.172913      0.686437       0.002448
  ZCCHC24                         −1.06124   0.3460263     0.172931      0.692381       0.00271
  CCL18                           −1.04882   0.3503516     0.180175      0.681262       0.001993

HR -- hazard ration; CI -- confidence interval; Beta -- regression coefficient; AML -- acute myeloid leukemia.

###### 

KEGG signaling pathway enrichment.

  KEGG ID     KEGG term                                   No.   FDR        Genes
  ----------- ------------------------------------------- ----- ---------- ------------------------
  hsa 04972   Pancreatic secretion                        3     0.000131   ATP2B1, ATP2A1, ATP2A3
  hsa04020    Calcium signaling pathway                   3     0.000131   ATP2B1, ATP2A1, ATP2A3
  hsa04650    Natural killer cell mediated cytotoxicity   3     0.006809   BRAF, KLRD1, LAT
  hsa05010    Alzheimer's disease                         3     0.013968   ATP2A1, ATP2A3, NDUFA7

FDR -- false discovery rate; No. -- number of genes.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection

[^8]: These authors contribute to the article equally
